Market
UCL DMT trial shows significant reduction in alcohol intake by end of 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Results published by University College London or in a peer-reviewed journal
Story
UCL to Trial Dimethyltryptamine (DMT) on UK Volunteers to Combat Alcohol Misuse
Jan 19, 2025, 12:45 PM
Scientists at University College London (UCL) are set to trial the psychedelic drug dimethyltryptamine (DMT) on UK volunteers in an effort to address alcohol misuse. The study aims to determine whether a single dose of this powerful hallucinogen can assist individuals in reducing their alcohol intake. DMT, known for its use in traditional healing ceremonies, has garnered interest as a potential therapeutic agent in treating substance dependence. This initiative aligns with broader discussions in the European Union regarding the regulation and funding of psychedelic therapies, as various organizations advocate for equitable access to such treatments across member states.
View original story
Similar markets
10% or less increase • 25%
More than 30% increase • 25%
21-30% increase • 25%
11-20% increase • 25%
Moderate positive impact • 25%
No significant impact • 25%
Significant positive impact • 25%
Negative impact • 25%
Lowered significantly • 25%
Increased • 25%
Remains the same • 25%
Lowered slightly • 25%
Yes • 50%
No • 50%
NGO-led campaigns • 25%
No campaigns • 25%
Government-led campaigns • 25%
Joint government and NGO campaigns • 25%
Yes • 50%
No • 50%
Safe but not effective • 25%
Safe and effective • 25%
Effective but not safe • 25%
Neither safe nor effective • 25%
Lifestyle Changes • 25%
Other • 25%
Genetic Interventions • 25%
Medication • 25%
